CAMBRIDGE, Mass. & BOTHELL, Wash.--(BUSINESS WIRE)--Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited (TSE:4502) and Seattle Genetics, Inc. (Nasdaq: SGEN), today reported data from a sub-analysis of the registration-enabling phase II clinical trial of ADCETRIS™ (brentuximab vedotin) in relapsed or refractory systemic anaplastic large cell lymphoma (sALCL). ADCETRIS is an antibody-drug conjugate (ADC) directed to CD30, which is highly expressed in sALCL. The data were presented today during a poster presentation at the 16th Congress of the European Hematology Association (EHA) being held June 9-12, 2011 in London.
